Results 171 to 180 of about 28,757,677 (326)

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

Complement therapeutic factor H-IgG proteins as pre-exposure prophylaxes against Lyme borreliae infections. [PDF]

J Immunol
McKaig CW, Malfetano J, Tran Y, Yang X, Pal U, Wycoff K, Lin YP.   +6 more
europepmc   +1 more source

Two separate genes regulate self-Ia and carrier recognition in H-2-restricted helper factors secreted by hybridoma cells. [PDF]

, 1981
Peter Lonai, S Bitton, H.F.J. Savelkoul, Joseph Puri, Günter J. Hämmerling   +4 more
openalex   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias, Ana Oitabén, Sonia Zumalave, Bernardo Rodriguez‐Martin, María Gallardo‐Gómez, Martín Santamarina, Ana Pequeño‐Valtierra, Laura Juaneda‐Magdalena, Ramón García‐Escudero, José Luis López‐Cedrún, Máximo Fraga, José M. C. Tubio, Mónica Martínez‐Fernández   +12 more
wiley   +1 more source

The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system. [PDF]

, 1983
E.J. Brown, Keith A. Joiner, T A Gaither, Carl H. Hammer, Martin Frank   +4 more
openalex   +1 more source

Factor H-related proteins determine complement-activating surfaces.

Trends in immunology, 2015
M. Józsi, A. Tortajada, B. Uzonyi, E. Goicoechea de Jorge, S. Rodríguez de Córdoba   +4 more
semanticscholar   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Factor H-related 2 levels dictate FHR dimer composition. [PDF]

Sci Rep
Veuskens BRJ, Brouwer MC, van Mierlo G, Geissler J, van Leeuwen K, Derlagen M, Keijzer NCH, Hoogenboezem M, Kuijpers TW, Pouw RB.   +9 more
europepmc   +1 more source

A high‐resolution ¹H‐NMR study of human transforming growth factor α [PDF]

, 1989
Michael J. Tappin, Roger Cooke, J.E. Fitton, Iain D. Campbell   +3 more
openalex   +1 more source

Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy.

Journal of the American Society of Nephrology, 2015
Li Zhu, Ya-Ling Zhai, Feng-mei Wang, P. Hou, J. Lv, Da-min Xu, S. Shi, Lijun Liu, F. Yu, Ming-hui Zhao, J. Novak, A. Gharavi, Hong Zhang   +12 more
semanticscholar   +1 more source